<!DOCTYPE html>
<html lang="en" dir="ltr">

<head>
  <meta charset="utf-8">
  <title>Fibrodysplasia Ossificans Progressiva | References</title>
  <link rel="stylesheet" href="style.css">
  <link rel="shortcut icon" href="./src/img/icon.ico">
  <script src="https://code.jquery.com/jquery-3.5.1.min.js" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script>
  <script>
    $(function() {
      $('#header').load('header.html');
    });
  </script>
</head>

<body>
  <div class="content">
    <div id='header'></div>
    <h1>References</h1>
    <h2>Works Cited</h2>
    <br>
    <p>Al-Haggar, Mohammad, et al. “Sporadic Fibrodysplasia Ossificans Progressiva in an Egyptian Infant with C.617G > A Mutation in ACVR1 Gene: A Case Report and Review of Literature.” Case Reports in Genetics, Hindawi Publishing Corporation, 2013,
      www.ncbi.nlm.nih.gov/pmc/articles/PMC3566490/.<br><br>
      “BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva.” BioCryst Pharmaceuticals,
      ir.biocryst.com/news-releases/news-release-details/biocryst-announces-positive-phase-1-results-bcx9250-oral-alk-2.<br><br>
      Cohen RB;Hahn GV;Tabas JA;Peeper J;Levitz CL;Sando A;Sando N;Zasloff M;Kaplan FS; “The Natural History of Heterotopic Ossification in Patients Who Have Fibrodysplasia Ossificans Progressiva. A Study of Forty-Four Patients.” The Journal of Bone
      and Joint Surgery. American Volume, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/8423182/.<br><br>
      “International Fibrodysplasia Ossificans Progressiva Association.” IFOPA, www.ifopa.org/.<br><br>
      Martelli, Anderson, and Arnaldo Rodrigues Santos. “Cellular and Morphological Aspects of Fibrodysplasia Ossificans Progressiva. Lessons of Formation, Repair, and Bone Bioengineering.” Organogenesis, Taylor &amp; Francis, 2014,
      www.ncbi.nlm.nih.gov/pmc/articles/PMC4750545/.
    </p>
  </div>
</body>

</html>